Breaking Finance News

Esperion Therapeutics Inc (NASDAQ:ESPR) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $12.24, Esperion Therapeutics Inc (NASDAQ:ESPR) traded 1.58% higher on the day. With the last close down -11.87% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the same period. Esperion Therapeutics Inc has recorded a 50-day average of $12.38 and a two hundred day average of $13.89. Volume of trade was up over the average, with 428,358 shares of ESPR changing hands over the typical 357,142

Zacks Investment Research has downgraded Esperion Therapeutics Inc (NASDAQ:ESPR) to Hold in a statement released on 10/17/2016.

On 10/05/2016, Zacks Investment Research released a statement on Esperion Therapeutics Inc (NASDAQ:ESPR) upped the target price from $0.00 to $16.00 that suggested an upside of 0.13%.

See Chart Below

Esperion Therapeutics Inc (NASDAQ:ESPR)

Esperion Therapeutics Inc has a 52 week low of $9.58 and a 52 week high of $30.41 The company’s market cap is currently $0.

In addition to Zacks Investment Research reporting its target price, a total of 12 firms have reported on the stock. The consensus target price is $32.67 with 3 firms rating the stock a strong buy, 8 firms rating the stock a buy, 2 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.

About Esperion Therapeutics Inc (NASDAQ:ESPR)

Esperion Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of patients with elevated LDL-C. The Company's segment is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C. The Company's lead product candidate is ETC-1002, or bempedoic acid. The Company is engaged in conducting a global Phase III long-term safety and tolerability study of bempedoic acid in patients with hyperlipidemia whose LDL-C is not adequately controlled with low- and moderate-dose statins. Bempedoic acid is an inhibitor of ATP Citrate Lyase (ACL), a well-characterized enzyme on the cholesterol biosynthesis pathway. Bempedoic acid inhibits cholesterol synthesis in the liver, decreases intracellular cholesterol and up-regulates LDL-receptors.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.